Gli2 silencing enhances TRAIL-induced apoptosis and reduces tumor growth in human hepatoma cells in vivo

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: Cancer J Clin 2005; 55(2):74-108; PMID:15761078
   PubMed Web of Science ®Google Scholar
• Page JM, Harrison SA. NASH and HCC. Clin Liver Dis 2009; 13(4):631-47; PMID:19818310
   PubMed Web of Science ®Google Scholar
• Gores GJ, Kaufmann SH. Is TRAIL hepatotoxic? Hepatology 2001; 34(1):3-6; PMID:11431726
   PubMed Web of Science ®Google Scholar
• Wang P, Song JH, Song DK, Zhang J, Hao C. Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis. Cell Signalling 2006; 18(9):1528-35; PMID:16442262
   PubMed Web of Science ®Google Scholar
• Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC, Tyrrell DL, Kneteman NM. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 2004; 64(23):8502-6; PMID:15574753
   PubMed Web of Science ®Google Scholar
• Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, Takase K, Moriyama M, Nakano T, Suzuki A. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 2000; 32(3):482-90; PMID:10960439
   PubMed Web of Science ®Google Scholar
• Carlisi D, Lauricella M, D’Anneo A, Emanuele S, Angileri L, Di Fazio P, Santulli A, Vento R, Tesoriere G. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer 2009; 45(13):2425-38; PMID:19643600
   PubMed Web of Science ®Google Scholar
• Jin CY, Park C, Moon SK, Kim GY, Kwon TK, Lee SJ, Kim WJ, Choi YH. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage. Anti-Cancer Drugs 2009; 20(8):713-22; PMID:19617819
   PubMed Web of Science ®Google Scholar
• Um HJ, Oh JH, Kim YN, Choi YH, Kim SH, Park JW, Kwon TK. The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP. Chemico-Biol Interact 2010; 186(1):36-42; PMID:20403343; http://dx.doi.org/10.1016/j.cbi.2010.04.013
   PubMed Web of Science ®Google Scholar
• Zhang S, Li G, Zhao Y, Liu G, Wang Y, Ma X, Li D, Wu Y, Lu J. Smac mimetic SM-164 potentiates APO2LTRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells. PloS One 2012; 7(12): e51461; PMID:23240027; http://dx.doi.org/10.1371/journal.pone.0051461
   PubMedGoogle Scholar
• Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, Miller R, Liao J, Yi H, Liu M, et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther 2011; 10(5):902-14; PMID:21372226; http://dx.doi.org/10.1158/1535-7163.MCT-10-0864
   PubMed Web of Science ®Google Scholar
• Huang S, Okumura K, Sinicrope FA. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res: Off J Am Assoc Cancer Res 2009; 15(1):150-9; PMID:19118042; http://dx.doi.org/10.1158/1078-0432.CCR-08-1575
   PubMed Web of Science ®Google Scholar
• Sicklick JK, Li YX, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P, Ludlow JW, Owzar K, Chen W, Torbenson MS, et al. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006; 27(4):748-57; PMID:16339184
   PubMed Web of Science ®Google Scholar
• Patil MA, Zhang J, Ho C, Cheung ST, Fan ST, Chen X. Hedgehog signaling in human hepatocellular carcinoma. Cancer Biol Ther 2006; 5(1):111-7; PMID:16397407
   PubMed Web of Science ®Google Scholar
• Huang S, He J, Zhang X, Bian Y, Yang L, Xie G, Zhang K, Tang W, Stelter AA, Wang Q, et al. Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 2006; 27(7):1334-40; PMID:16501253
   PubMed Web of Science ®Google Scholar
• Ikram MS, Neill GW, Regl G, Eichberger T, Frischauf AM, Aberger F, Quinn A, Philpott M. GLI2 is expressed in normal human epidermis and BCC and induces GLI1 expression by binding to its promoter. J Invest Dermatol 2004; 122(6):1503-9; PMID:15175043; http://dx.doi.org/10.1111/j.0022-202X.2004.22612.x
   PubMed Web of Science ®Google Scholar
• Siegelin MD, Siegelin Y, Habel A, Rami A, Gaiser T. KAAD-cyclopamine augmented TRAIL-mediated apoptosis in malignant glioma cells by modulating the intrinsic and extrinsic apoptotic pathway. Neurobiol Dis 2009; 34(2):259-66; PMID:19385057; http://dx.doi.org/10.1016/j.nbd.2009.01.012
   PubMed Web of Science ®Google Scholar
• Zhang D, Liu J, Wang Y, Chen J, Chen T. shRNA-mediated silencing of Gli2 gene inhibits proliferation and sensitizes human hepatocellular carcinoma cells towards TRAIL-induced apoptosis. J Cell Biochem 2011; 112(11):3140-50; PMID:21695716; http://dx.doi.org/10.1002/jcb.23240
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2LTRAIL). J Clin Oncol: Off J Am Soc Clin Oncol 2008; 26(21):3621-30; PMID:18640940; http://dx.doi.org/10.1200/JCO.2007.15.7198
   PubMed Web of Science ®Google Scholar
• Shin EC, Seong YR, Kim CH, Kim H, Ahn YS, Kim K, Kim SJ, Hong SS, Park JH. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 2002; 34(2):114-22; PMID:12085986; http://dx.doi.org/10.1038/emm.2002.17
   PubMed Web of Science ®Google Scholar
• Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004; 11 Suppl 1:86-96; PMID:15105837; http://dx.doi.org/10.1038/sj.cdd.4401437
   PubMed Web of Science ®Google Scholar
• Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002; 21(15):2283-94; PMID:11948412; http://dx.doi.org/10.1038/sj.onc.1205258
   PubMed Web of Science ®Google Scholar
• Han SI, Kim YS, Kim TH. Role of apoptotic and necrotic cell death under physiologic conditions. BMB Rep 2008; 41(1):1-10; PMID:18304444; http://dx.doi.org/10.5483/BMBRep.2008.41.1.001
   PubMed Web of Science ®Google Scholar
• Kim Y, Yoon JW, Xiao X, Dean NM, Monia BP, Marcusson EG. Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res 2007; 67(8):3583-93; PMID:17440069; http://dx.doi.org/10.1158/0008-5472.CAN-06-3040
   PubMed Web of Science ®Google Scholar
• Narita S, So A, Ettinger S, Hayashi N, Muramaki M, Fazli L, Kim Y, Gleave ME. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 2008; 14(18):5769-77; PMID:18794086; http://dx.doi.org/10.1158/1078-0432.CCR-07-4282
   PubMed Web of Science ®Google Scholar
• Regl G, Kasper M, Schnidar H, Eichberger T, Neill GW, Philpott MP, Esterbauer H, Hauser-Kronberger C, Frischauf AM, Aberger F. Activation of the BCL2 promoter in response to HedgehogGLI signal transduction is predominantly mediated by GLI2. Cancer Res 2004; 64(21):7724-31; PMID:15520176; http://dx.doi.org/10.1158/0008-5472.CAN-04-1085
   PubMed Web of Science ®Google Scholar
• Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002; 277(25):22320-9; PMID:11940602; http://dx.doi.org/10.1074/jbc.M202458200
   PubMed Web of Science ®Google Scholar
• Roth W, Reed JC FLIP protein and TRAIL-induced apoptosis. Vitam Horm 2004; 67:189-206.
   PubMed Web of Science ®Google Scholar
• Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 2004; 64(19):7086-91; PMID:15466204; http://dx.doi.org/10.1158/0008-5472.CAN-04-1498
   PubMed Web of Science ®Google Scholar
• Brooks AD, Sayers TJ. Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis. Cancer Immunol Immunother 2005; 54(5):499-505; PMID:15614529; http://dx.doi.org/10.1007/s00262-004-0595-8
   PubMed Web of Science ®Google Scholar